advanced search

OCULAR

OCULAR
DRUG DELIVERY PLATFORM DRIVES NEW OPPORTUNITIES FOR CONTINUOUS-DELIVERY GLAUCOMA TREATMENT
Harsh Patel, Cyonna Holmes and Brian Wilson discuss how Celanese’s VitalDose® EVA drug delivery platform can help reduce intraocular pressure by creating a desired therapeutic release profile.
OCULAR
NOVELIA®: A CLEAR VISION FOR EYE CARE FOR PATIENTS GLOBALLY
Zoë Davidson discusses the benefits of Novelia®, Nemera’s alternative to sterile filters for multidose eye droppers for preservative-free formulations.
GREEN THINKING: HOW TO BECOME A MORE SUSTAINABLE ORGANISATION
SUSTAINABILITY
André Jansen
IGS GeboJagema
GREEN THINKING: HOW TO BECOME A MORE SUSTAINABLE ORGANISATION
André Jansen and Ron Cisliek describe how high-precision mould maker IGS GeboJagema is fostering a culture of “green thinking” and making sustainability a core part of its business.
ACQUIRING A LIQUID BIOPSY INCIDENTAL TO INTRAVITREAL INJECTION
EARLY INSIGHT
Dr Alex Tumlinson
Twenty/Twenty Therapeutics
ACQUIRING A LIQUID BIOPSY INCIDENTAL TO INTRAVITREAL INJECTION
Alexandre Tumlinson introduces Twenty/Twenty Therapeutics' VitreoDx injection system to address emerging trends in intravitreal therapeutics.
OPTIMISING MICROLITRE DOSING: CASE STUDY WITH INTRAVITREAL INJECTION
OCULAR
Yuki Takeuchi
Terumo Medical Care Solutions
OPTIMISING MICROLITRE DOSING: CASE STUDY WITH INTRAVITREAL INJECTION
Yuki Takeuchi and Richard Whelton discuss the challenges of delivering intravitreal injections and how the combination of Terumo’s PLAJEX™ prefillable syringes with Congruence’s Microlitre Dosing Syringe system is able to address them.
OVERCOMING CHALLENGES WHEN DEVELOPING OLIGONUCLEOTIDES FOR OPHTHALMIC DRUGS
EXPERT VIEW
Dr Shiyan Chen
OVERCOMING CHALLENGES WHEN DEVELOPING OLIGONUCLEOTIDES FOR OPHTHALMIC DRUGS
Shiyan Chen and Binbin Tian discuss the use of oligonucleotides for ophthalmic applications, including their potential uses, advantages, challenges and difficulties when it comes to pharmacokinetic and drug metabolism studies.
INTRAVITREAL INJECTIONS – MORE THAN MEETS THE EYE: A TECHNICAL VIEW OF PRODUCT USE
OCULAR
Dr Andrea Allmendinger
ten23 health
INTRAVITREAL INJECTIONS – MORE THAN MEETS THE EYE: A TECHNICAL VIEW OF PRODUCT USE
Andrea Allmendinger and Hanns-Christian Mahler highlight the technical challenges of intravitreal administration and considerations from the ophthalmologist’s and patient’s perspectives.
GROUNDBREAKING TREND FOR PRESERVATIVE-FREE MULTIDOSE EYE DROPS IN THE US
OCULAR
Rouven Kraus
Aero Pump
GROUNDBREAKING TREND FOR PRESERVATIVE-FREE MULTIDOSE EYE DROPS IN THE US
Rouven Kraus discusses the increasing trend towards preservative-free formulations in ophthalmic drug delivery and the challenges presented by regulatory demands on new drug products in the space.
MISTGO<sup>®</sup> – A NEW MICRODOSING EYE MEDICATION DELIVERY SYSTEM
EARLY INSIGHT
Rie Saabye
EYE-GO
MISTGO® – A NEW MICRODOSING EYE MEDICATION DELIVERY SYSTEM
Rie Saabye and Morten Jacobsen discuss the benefits of a new microdosing eye medication delivery system for chronic ophthalmic diseases, such as dry eye disease and glaucoma.
TOPICAL DRUG ADMINISTRATION FOR THE POSTERIOR SEGMENT
EXPERT VIEW
Dr David Bingaman
TOPICAL DRUG ADMINISTRATION FOR THE POSTERIOR SEGMENT
David Bingaman explores the potential benefits of topical administration for diseases affecting the posterior segment of the eye.
BEYOND THE EYEDROPPER BOTTLE – THREE WAYS TO IMPROVE ADHERENCE
EXPERT VIEW
Dr Nathan Wilkinson
BEYOND THE EYEDROPPER BOTTLE – THREE WAYS TO IMPROVE ADHERENCE
Nathan Wilkinson, Catherine Wyman and Matt Parker discuss the future outlook of ophthalmic drug delivery beyond the traditional eyedropper bottle, including new delivery technologies, sustained-release therapeutics and digital healthcare applications.
A SIGHT FOR SORE EYES: CHALLENGES & INNOVATIONS IN OPHTHALMIC DRUG DELIVERY
EXPERT VIEW
Dr Ethan Miller
A SIGHT FOR SORE EYES: CHALLENGES & INNOVATIONS IN OPHTHALMIC DRUG DELIVERY
Ethan Miller and Kristien De Clercq discuss recent advancements and current challenges in the field of ophthalmology, including the trend towards preservative-free multidose delivery systems, delivering smaller topical volumes with increased drug efficacy, slow-release injections for delivery to the posterior of the eye and the exciting field of gene therapy.
SILICONE-OIL-FREE PREFILLED SYRINGE SYSTEMS – GUIDANCE FOR SELECTING THE APPROPRIATE PACKAGING MATERIALS AND FOR SILICONISATION
PREFILLED SYRINGES
Bernd Zeiss
Gerresheimer
SILICONE-OIL-FREE PREFILLED SYRINGE SYSTEMS – GUIDANCE FOR SELECTING THE APPROPRIATE PACKAGING MATERIALS AND FOR SILICONISATION
Bernd Zeiss addresses the influence of silicone oil on syringe systems and highlights the advantages and possibilities of novel silicone-oil-free prefillable syringes, both for glass and for plastic syringes.
ANTICIPATING & MITIGATING CHALLENGES IN THE COMMERCIALISATION OF PREFILLED SYRINGES & INJECTION DEVICES – A TECHNICAL DRUG PRODUCT PERSPECTIVE
PREFILLED SYRINGES
Dr Andrea Allmendinger
ten23 health
ANTICIPATING & MITIGATING CHALLENGES IN THE COMMERCIALISATION OF PREFILLED SYRINGES & INJECTION DEVICES – A TECHNICAL DRUG PRODUCT PERSPECTIVE
Andrea Allmendinger and Hanns-Christian Mahler both at ten23 health, provide an insight into the challenges of integrated development of drug product and device design and fill-finish manufacturing operations.
SUSTAINABILITY MEASURES ARE THE KEY TO MEETING ESG COMMITMENTS
SUSTAINABILITY
Matthias Birkhoff
Aptar Pharma
SUSTAINABILITY MEASURES ARE THE KEY TO MEETING ESG COMMITMENTS
Matthias Birkhoff and Christophe Marie discuss the advances Aptar Pharma has made in delivering on its sustainability objectives.
DISSECTING THE DELICATE DELIVERY PROCESS FOR OCULAR GENE THERAPY
EXPERT VIEW
Dr Yongdong Zhou
DISSECTING THE DELICATE DELIVERY PROCESS FOR OCULAR GENE THERAPY
Yongdong Zhou considers the challenges of ocular gene therapy delivery approaches.
WHY GENE THERAPY IS PERFECT FOR TREATING OCULAR DISEASES
EXPERT VIEW
Dr Yongdong Zhou
WHY GENE THERAPY IS PERFECT FOR TREATING OCULAR DISEASES
Yongdong Zhou discusses the applications, advantages and challenges of gene therapy in the ophthalmic sector.
INTERVIEW: Natalia Servol, Unither Pharmaceuticals
INTERVIEW
Natalia Servol
Unither Pharmaceuticals
INTERVIEW: Natalia Servol, Unither Pharmaceuticals
In this interview, Natalia Servol, Head of Unither Pharmaceuticals’ Ophthalmic Business, speaks about the company's equipment for compounding and fill-finish of preservative-free products into multidose bottles, part of Unither’s unique and innovative preservative-free multidose offering for partners.
THE DEMAND FOR METERED DOSE EYE DROPS: A DOSE DELIVERY STUDY
OCULAR
Rouven Kraus
Aero Pump
THE DEMAND FOR METERED DOSE EYE DROPS: A DOSE DELIVERY STUDY
Rouven Kraus discusses a dose delivery study comparing various delivery technologies designed to meet the demand for metered dose eye drops.
A CULTURE OF COLLABORATION INSPIRES INNOVATION AND LIFE-CHANGING THERAPIES
OCULAR
Justin Westendorf
Phillips-Medisize
A CULTURE OF COLLABORATION INSPIRES INNOVATION AND LIFE-CHANGING THERAPIES
Justin Westendorf describes the company’s collaborative approach with a leader in ocular disease treatments to overcome technical and stakeholder challenges.
AN EYE ON THE FUTURE OF PRESERVATIVE-FREE DROPS
OCULAR
Alexandra Ritter
Aptar Pharma
AN EYE ON THE FUTURE OF PRESERVATIVE-FREE DROPS
Alexandra Ritter and Matthias Birkhoff discuss the importance of the regulatory support the company offers to its customers for preservative-free ophthalmic platforms in the face of increasingly stringent regulatory requirements from both the EU EMA and US FDA, and describe new opportunities and growing demand for a wider range of multidose preservative-free ophthalmic drug-device combinations, including for indications such as dry-eye and glaucoma.
SUSTAINED, CONTROLLED DRUG DELIVERY TO THE EYE
OCULAR
Dr Harsh Patel
Celanese
SUSTAINED, CONTROLLED DRUG DELIVERY TO THE EYE
Harsh Patel, Cyonna Holmes and Brian Wilson consider the challenges and advances in sustained-release ocular drug delivery.
A NEW PLATFORM FOR SUPRACHOROIDAL DRUG DELIVERY USING STANDARD NEEDLES
EARLY INSIGHT
Timo Kangastupa
Visionisti
A NEW PLATFORM FOR SUPRACHOROIDAL DRUG DELIVERY USING STANDARD NEEDLES
Timo Kangastupa discusses the potential of the suprachoroidal space for highly effective, specifically targeted drug delivery to the choroid and retina, and how Visionisti’s technology simplifies and standardises the procedure, enabling the use of standard commercially available needles for suprachoroidal delivery.
HOW TEN23 HEALTH IS MEETING DEVELOPMENTAL CHALLENGES FOR INTRAVITREAL PRODUCTS
OCULAR
Dr Andrea Allmendinger
ten23 health
HOW TEN23 HEALTH IS MEETING DEVELOPMENTAL CHALLENGES FOR INTRAVITREAL PRODUCTS
Andrea Allmendinger and Hanns-Christian Mahler highlight new regulatory and quality requirements for intravitreal applications and discuss technical challenges during drug product technical development and manufacturing.
PHARMACOKINETIC MODELS: INDISPENSABLE TOOLS FOR OPHTHALMIC DRUG DEVELOPMENT
EARLY INSIGHT
Dr Eva M del Amo
University of Eastern Finland DrugTech
PHARMACOKINETIC MODELS: INDISPENSABLE TOOLS FOR OPHTHALMIC DRUG DEVELOPMENT
Eva del Amo presents an overview of pharmacokinetic models for ophthalmic drugs, and discusses the value of these models for future drug development in the sector.
ENVISIONING NEW HORIZONS IN OCULAR DRUG DELIVERY
EXPERT VIEW
Dr Jay S Duker
ENVISIONING NEW HORIZONS IN OCULAR DRUG DELIVERY
Jay S Duker discusses the history and future of ocular drug delivery, with a special focus on posterior segment diseases and the battle to overcome significant patient and caregiver burdens.
OPHTHALMIC INJECTION OF VISCOUS FORMULATIONS – WHY UNIQUE NEEDS REQUIRE A NOVEL DELIVERY APPROACH
OCULAR
Dr Gautam N Shetty
Congruence Medical Solutions
OPHTHALMIC INJECTION OF VISCOUS FORMULATIONS – WHY UNIQUE NEEDS REQUIRE A NOVEL DELIVERY APPROACH
Guatam Shetty and Richard Whelton outline the key considerations related to ophthalmic injection of viscous formulations and propose an innovative, user-validated and fully mechanical device-based solution.
KEEPING UP WITH THE DEMAND FOR EFFECTIVE OPHTHALMIC DRUGS
EXPERT VIEW
Robert Lee
KEEPING UP WITH THE DEMAND FOR EFFECTIVE OPHTHALMIC DRUGS
Robert Lee explores the growth of the ophthalmic drug market and discuss the challenges that pharma companies may face when creating drugs to treat some of the most common ocular indications.
EIGHT ESSENTIAL SUSTAINABILITY TERMS FOR THE MEDICAL DEVICE INDUSTRY
EXPERT VIEW
Charlie Dean
EIGHT ESSENTIAL SUSTAINABILITY TERMS FOR THE MEDICAL DEVICE INDUSTRY
Charlie Dean, Kay Sinclair and Brennan Miles provide an overview of eight terms key to a common understanding in the ongoing, and crucial, discussion surrounding sustainability.
OVERCOMING DEVELOPMENT OBSTACLES TO THE DELIVERY OF EFFECTIVE OCULAR THERAPY
EXPERT VIEW
Robert Lee
OVERCOMING DEVELOPMENT OBSTACLES TO THE DELIVERY OF EFFECTIVE OCULAR THERAPY
Robert Lee discusses the growth of the ocular drug delivery market, the challenges formulators face in developing novel ocular technologies, and the role contract development and manufacturing organisations have to play in this growing market segment.
OPHTHALMIC DRUGS: PATHWAY TO OVERCOME PRIMARY PACKAGING AND DRUG PRODUCT MANUFACTURING CHALLENGES
OCULAR
Rainer Glockler
ten23 health
OPHTHALMIC DRUGS: PATHWAY TO OVERCOME PRIMARY PACKAGING AND DRUG PRODUCT MANUFACTURING CHALLENGES
Rainer Glöckler, Carole Delauney, Dr Nicolas Eon and Katsuyuki Takeuchi discuss the myriad complexities of developing drug products for intravitreal injection, and how the partnership between swissfillon and Terumo can ease and accelerate these products to market. The first article, published in April, covered how swissfillon’s state-of-the-art filling line meets the complex requirements of ophthalmic drug products.
CONSIDERATIONS FOR OPHTHALMIC DRUG DELIVERY AND DEVELOPMENT
EXPERT VIEW
Robert Lee
CONSIDERATIONS FOR OPHTHALMIC DRUG DELIVERY AND DEVELOPMENT
Robert Lee discusses recent advances in ophthalmic dosage forms and how companies are meeting these challenges to better serve their customers.
STATE-OF-THE-ART SOLUTIONS FOR OPHTHALMIC STERILE DRUG PRODUCT MANUFACTURING
OCULAR
Rainer Glockler
ten23 health
STATE-OF-THE-ART SOLUTIONS FOR OPHTHALMIC STERILE DRUG PRODUCT MANUFACTURING
In the first in a series of two articles, Rainer Glöckler and Carole Delauney discuss how the company’s state-of-the-art filling line meets the requirements and complexities that are particular to ophthalmic drug product manufacturing. The second article, to be published in May, will explore partnerships between pharma, CDMOs and syringe manufacturers in more detail.
THE PIVOTAL ROLE PLAYED BY DEVICE DEVELOPERS TO IMPROVE PATIENT EYE CARE
OCULAR
Zoe Davidson
Nemera
THE PIVOTAL ROLE PLAYED BY DEVICE DEVELOPERS TO IMPROVE PATIENT EYE CARE
Zoë Davidson and Carolyn Rose discuss the challenges glaucoma and dry eye patients face with eye drop administration and present the Novelia® system featuring patented PureFlow® technology, which controls the medication flow.
DRUG DELIVERY TO THE EYE: OVERCOMING THE CHALLENGES OF INTRAVITREAL PREFILLED SYRINGES
EXPERT VIEW
Dr Suresh Gupta
DRUG DELIVERY TO THE EYE: OVERCOMING THE CHALLENGES OF INTRAVITREAL PREFILLED SYRINGES
Suresh Gupta discusses the challenges of developing a PFS product for intravitreal injection, highlighting how designing for the intravitreal space, rather than the standard parenteral, imposes a number of additional requirements on the design.
INTERVIEW WITH SAI SHANKAR, ADAM SHAIN & MARCUS BATES
INTERVIEW
Sai Shankar
Aptar Pharma
INTERVIEW WITH SAI SHANKAR, ADAM SHAIN & MARCUS BATES
Sai Shankar, Adam Shain and Marcus Bates discuss the full potential of connectivity, coronavirus as a potential accelerator of adoption, and the place of connected drug delivery systems within Aptar Pharma’s broader offering to industry.
EU MDR DEADLINE DELAY: WHAT DOES IT MEAN FOR THE MEDICAL DEVICE INDUSTRY?
EXPERT VIEW
Beth Crandall
EU MDR DEADLINE DELAY: WHAT DOES IT MEAN FOR THE MEDICAL DEVICE INDUSTRY?
With the compliance deadline for the EU Medical Device Regulation recently delayed by a year due to the novel coronavirus pandemic, Beth Crandall looks at what it means for the medical device industry.
INTERVIEW WITH DR SRI MUDUMBA, SANTEN & DR GAUTAM SHETTY, CONGRUENCE
INTERVIEW
Dr Gautam N Shetty
Congruence Medical Solutions
INTERVIEW WITH DR SRI MUDUMBA, SANTEN & DR GAUTAM SHETTY, CONGRUENCE
In this interview, Dr Sri Mudumba, Santen, and Dr Gautam N Shetty, Congruence Medical Solutions, share insights from their experience of working together in developing the MDS for ophthalmic injections.
Top